SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Abroad (travel likely)RecruitingPHASE3

Conditions

Hemophilia A

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Contact: Study coordinator (Robert Sidonio, MD) · robert.sidonio.jr@emory.edu · 4047851637
Emory University Hospital, Atlanta, Georgia, United States

Study leads

Robert Sidonio, MD
Principal Investigator
Emory University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

Hemophilia A

Abroad (travel likely)Recruiting

Little Rock, United States · Palo Alto, United States

Pharmacokinetic-guided Dosing of Emicizumab

Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe

Abroad (travel likely)RecruitingPHASE4

Nijmegen, Netherlands · Maastricht, Netherlands

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hemophilia A

Abroad (travel likely)RecruitingPHASE3

Kashihara-shi, Japan · Shinjuku-Ku, Japan

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Hemophilia

Abroad (travel likely)RecruitingPHASE3

Los Angeles, United States · Orange, United States